By: Natalie Johnson
Biopharma boards have spent the last decade recruiting for the same profile: deep scientific credibility, hard commercial numbers, a track record of moving assets through development. Those criteria are not wrong, but they are incomplete, and the gap is becoming expensive. Peter S. Kaplan, an executive recruiter who has spent 25 years placing leaders across the sector, argues that the industry has been measuring executives against the molecule rather than against the person who has to take it. “The best executives do not confuse knowing the science with understanding the experience of living with the disease,” he says. “They value both, and build decision-making processes that bring them together.” That distinction sounds soft until a therapy reaches market with a dosing regimen patients cannot sustain, a diagnostic pathway clinicians will not adopt, or an access model that collapses on contact with a working family’s calendar. Commercial failures in this industry are rarely failures of chemistry. They are failures of judgment about people.
What Patient-Centered Judgment Looks Like In A Candidate
The phrase “patient-centricity” has been drained of meaning by overuse, which is precisely why Kaplan treats it as something to be tested rather than asserted. He frames it as an additional assessment dimension that sits alongside technical expertise, execution, and business performance, not as a substitute for any of them. That framing matters. The moment patient focus becomes an alternative to commercial rigor, boards stop believing in it, and rightly so. Positioned as a fourth axis, it becomes a measurable attribute of leadership quality rather than a values statement on a careers page.
The test itself is unsentimental. Kaplan asks candidates to describe a decision they changed because of patient or caregiver input. He also asks how patient insights reached their leadership team, and what happened next. Both questions are difficult to fake, because both demand specifics. An executive who has genuinely absorbed patient input can name the decision, the input that shifted it, and the cost of reversing course. An executive who has not will produce an anecdote about a patient advocacy panel and move on. The second question is the sharper of the two. It asks about plumbing: whether the organization built a channel for patient insight to travel upward, and whether anything happened when it arrived. Plenty of companies have the listening exercise. Far fewer have the mechanism that converts listening into a changed plan.
Why The Mindset Cannot Live In Clinical Development Alone
The structural error most companies make is treating patient focus as the property of two functions. Clinical development owns it during trials, patient advocacy owns it afterward, and the rest of the enterprise proceeds on its own logic. Kaplan rejects that containment. “Patient-centricity is not confined to clinical development or patient advocacy,” he says. “It belongs in commercial, medical, manufacturing, finance, and operational decision-making as well.” Read that as an organizational design claim rather than a cultural one. Manufacturing decisions determine supply reliability. Finance decisions determine pricing and access. Operational decisions determine how quickly a patient moves from diagnosis to first dose. Each of those is a patient decision made by people who have never been asked to think of it that way.
Kaplan’s central argument is about a distinction the industry routinely collapses. “A therapy’s value should be considered not only in terms of its clinical effect, but also in the context of the life a patient must organize around receiving it,” he says. He separates a therapy’s clinical benefit from the burden associated with receiving it, noting that the FDA’s patient-focused framework encompasses patients’ needs and priorities, and that published research discusses how patient preferences can inform endpoints and assessments of meaningful benefit. The commercial consequence is direct. A drug that wins on efficacy and loses on burden will underperform its label, and the organization will spend years diagnosing a marketing problem that was actually a design problem. Kaplan puts the stake plainly: everyone in the company should carry this mindset, because families and caregivers are waiting for medicines that are, in some cases, life-saving.
The Leadership Restructuring Boards Should Be Preparing For
The timing of this argument is not incidental. As AI compresses discovery timelines, the constraint on a program shifts away from the science and toward the decisions surrounding it. Kaplan points to the target product profile, the diagnostic approach, and patient identification as critical to the success of a new therapy. All three are judgment calls made early, when a program has the fewest data points and the most optionality. Get patient identification wrong, and a technically excellent asset reaches the wrong population. Get the target product profile wrong, and a company optimizes for an endpoint that does not reflect meaningful benefit. Faster discovery does not fix those errors. It produces them sooner and at greater volume.
What follows is a change in the shape of leadership itself. “Boards and founders must prepare for a restructuring of executive leadership, shifting from siloed operations to enterprise-wide AI implementation, which will require a new way of thinking and operating, and this transition will be challenging for many organizations to get right,” Kaplan says. The two threads converge here. Enterprise-wide implementation means decisions that once belonged to one function now cut across several, which is exactly the condition under which a contained, departmental approach to patient focus stops working. Executives who can only reason within their silo will struggle in that structure regardless of how strong their functional record looks. The leaders worth recruiting now are the ones who can hold scientific rigor, commercial discipline, and the lived reality of the patient in the same decision, and who have the evidence to prove they have done it before.
Follow Peter S. Kaplan on LinkedIn for more insights on biopharma executive search, leadership assessment, and patient-centered decision-making.
